A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs NP-001 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Neuraltus Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2017 According to a Neuraltus Pharmaceuticals media release, the last patient visit is expected to occur in early 2018, with top line results anticipated in the first quarter of 2018.
    • 12 Jul 2017 Status changed from recruiting to active, no longer recruiting, according to a Neuraltus Pharmaceuticals media release.
    • 03 Apr 2017 According to a Neuraltus Pharmaceuticals media release, 87 of the planned 120 patients have been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top